Our Pipeline of Investigational Therapies

Surface Oncology® is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.

Surface’s pipeline spans compelling areas of discovery and development across four key areas of immune modulators to: activate both macrophages and natural killer cells, inhibit or deplete regulatory T cells and block suppressive cell signaling molecules, including cytokines and metabolites.

Wholly Owned Programs

Product Programs
Target
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
Worldwide rights
SRF617*
Target: CD39
CD39
Solid Tumors
Preclinical

* Surface has paused the clinical development of SRF617.

Licensed Programs

Product Programs
Target
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
Worldwide rights
NZV930
Target: CD73
CD73
Phase 1
GSK4381562
Target: PVRIG
PVRIG
Phase 1

Posters & Publications

The Surface team is committed to scientific exchange and continual learning, from each other, from our work and from experts around the world, to break through scientific challenges.

SRF388

Additional Resources

NZV930